登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《窦性心律患者心力衰竭患者缺乏阿司匹林的益处》

  • 来源专题：心血管疾病防治
  • 编译者： 张燕舞
  • 发布时间：2018-05-22

  • 阿司匹林对心力衰竭窦性心律患者的安全性和有效性尚不确定。 在对无心房颤动病史的心力衰竭患者进行的一项登记研究中，3840名服用小剂量阿司匹林的患者倾向于同样数量的未服用阿司匹林的患者倾向匹配阿司匹林和非阿司匹林组的死亡率和卒中率相似。 然而，在阿司匹林组中观察到较高的心力衰竭再入院率，这在一些但不是全部的先前研究中已经观察到。 阿司匹林的使用也与心肌梗塞风险增加有关，但不能排除残余混杂。 我们建议不要使用阿司匹林治疗心力衰竭患者，而没有针对这种治疗的具体指征。

    OBJECTIVES This study sought to assess safety and effectiveness of low-dose aspirin in heart failure (HF) not complicated by atrial fibrillation.

    BACKGROUND Despite lack of evidence, low-dose aspirin is widely used in patients with HF and sinus rhythm with and without prior ischemic heart disease.

    METHODS The study included 12,277 patients with new-onset HF during 2007 to 2012 who had no history of atrial fibrillation. Of 5,450 patients using low-dose aspirin at baseline, 3,840 were propensity matched to non-aspirin users in a 1:1 ratio. Propensity-matched Cox models were calculated with respect to the primary composite outcome of all-cause mortality, myocardial infarction, and stroke and the secondary outcomes of bleeding and HF readmission.

    RESULTS The composite outcome occurred in 1,554 (40.5%) patients in the aspirin group and 1,604 (41.8%) patients in the non-aspirin group. Aspirin use was not associated with an altered risk of composite outcome (hazard ratio [HR]: 0.98; 95% confidence interval [CI]: 0.91 to 1.05), but it was associated with an increased risk of myocardial infarction (HR: 1.34; 95% CI: 1.08 to 1.67), whereas no differences were observed in all-cause mortality and stroke. An increased risk of HF readmission was observed in the aspirin group (HR: 1.25; 95% CI: 1.17 to 1.33). No difference in bleeding was observed. In subgroup analyses on the basis of a history of ischemic heart disease, the results were similar to the main result.

    CONCLUSIONS No association was detected between low-dose aspirin use and the composite outcome of all-cause mortality,

169浏览量
原文链接
相关报告

  • 《射血分数保留的心力衰竭β受体阻滞剂缺乏》
    • 来源专题：心血管疾病防治
    • 编译者：张燕舞
    • 发布时间：2018-05-22
    • β受体阻滞剂治疗减少射血分数降低（HFrEF）的心力衰竭患者的症状和死亡率，但β受体阻滞剂治疗对保留射血分数（HFpEF）的心力衰竭患者的疗效尚不确定。 一项单独的患者级荟萃分析评估了β受体阻滞剂对窦性心律患者心衰的疗效。 β受体阻滞剂治疗可降低HFrEF患者的死亡率和心血管死亡率，但HFpEF患者的小部分患者没有获益，尽管置信区间很大。 如果没有其他适应症，我们建议不要使用HFpEF的β受体阻滞剂。 Aims Recent guidelines recommend that patients with heart failure and left ventricular ejection fraction (LVEF) 40-49% should be managed similar to LVEF ≥ 50%. We investigated the effect of beta-blockers according to LVEF in double-blind, randomized, placebo-controlled trials. Methods and results Individual patient data meta-analysis of 11 trials, stratified by baseline LVEF and heart rhythm (Clinicaltrials.gov: NCT0083244; PROSPERO: CRD42014010012). Primary outcomes were all-cause mortality and cardiovascular death over 1.3 years median follow-up, with an intention-to-treat analysis. For 14 262 patients in sinus rhythm, median LVEF was 27% (interquartile range 21-33%), including 575 patients with LVEF 40-49% and 244 ≥ 50%. Beta-blockers reduced all-cause and cardiovascular mortality compared to placebo in sinus rhythm, an effect that was consistent across LVEF strata, except forthose in the small subgroup with LVEF ≥ 50%. For LVEF 40-49%, death occurred in 21/292 [7.2%]randomized to beta-blockers compared to 35/283 [12.4%]with placebo; adjusted hazard ratio (HR) 0.59 [95% confidence interval (CI) 0.34-1.03]. Cardiovascular death occurred in 13/292 [4.5%]with beta-blockers and 26/283 [9.2%]with placebo; adjusted HR 0.48 (95% CI 0.24-0.97). Over a median of 1.0 years following randomization (n = 4601), LVEF increased with beta-blockers in all groups in sinus rhythm except LVEF ≥50%. For patients in atrial fibrillation at baseline (n = 3050), beta-blockers increased LVEF when < 50% at baseline, but did not improve prognosis. Conclusion Beta-blockers improve LVEF and prognosis for patients with heart failure in sinus rhythm with a reduced LVEF. The data are most robust for LVEF < 40%, but similar benefit was observed in the subgroup of patients with LVEF 40-49%.
    160浏览量
    原文链接

  • 《心力衰竭患者的坐位肺动脉压力监测:PROACTIVE-HF试验的结果》
    • 编译者：黄雅兰
    • 发布时间：2024-11-21
    • 背景 监测仰卧位肺动脉压力以指导心力衰竭(HF)治疗减少了部分患者的HF住院率。 目标 本研究的目的是评估使用Cordella肺动脉传感器管理坐位平均肺动脉压(mPAP)对心力衰竭患者预后的影响。 方法 继GUIDE-HF(血流动力学引导的心力衰竭管理试验)之后，在美国美国食品药品监督管理局的参与下，PROACTIVE-HF(一项前瞻性、多中心、开放标签、单组临床试验，评估Cordella肺动脉传感器系统在NYHA III级心力衰竭患者试验中的安全性和有效性)从随机试验改为单组、开放标签试验，在美国和欧洲的75个中心进行。符合条件的慢性心力衰竭患者具有NYHA功能III级症状，不考虑射血分数、近期心力衰竭住院和/或利钠肽升高。6个月时的主要疗效终点要求心衰住院率或全因死亡率低于0.43事件/患者的绩效目标，该目标是根据以前的血液动力学监测试验建立的。6个月时的主要安全性终点是无装置或系统相关并发症或压力传感器故障。 结果 从2020年2月7日到2023年3月31日，456名患者成功植入改良意向性治疗队列。6个月的事件发生率为0.15 (95% CI: 0.12-0.20)，显著低于绩效目标(0.15比0.43；P < 0.0001)。6个月内，装置或系统相关并发症的发生率为99.2%，传感器故障的发生率为99.8%。 结论 坐位mPAP的远程管理是安全的，并且导致低心衰住院率和死亡率。这些结果支持使用坐位mPAP监测，并扩展了越来越多的证据，即肺动脉压力引导管理改善心力衰竭的结果。(多中心、开放性、单组临床试验，评估Cordella肺动脉传感器系统在NYHA III级心力衰竭患者试验中的安全性和有效性[PROACTIVE-HF]；NCT04089059)
    84浏览量
    原文链接